Novartis AG (NVS)
NYSE: NVS · Real-Time Price · USD
97.11
+0.34 (0.35%)
Dec 20, 2024, 4:00 PM EST - Market closed
Novartis AG Employees
Novartis AG had 76,057 employees as of December 31, 2023. The number of employees decreased by 25,646 or -25.22% compared to the previous year.
Employees
76,057
Change (1Y)
-25,646
Growth (1Y)
-25.22%
Revenue / Employee
$656,613
Profits / Employee
$231,445
Market Cap
193.93B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 76,057 | -25,646 | -25.22% |
Dec 31, 2022 | 101,703 | -2,620 | -2.51% |
Dec 31, 2021 | 104,323 | -1,471 | -1.39% |
Dec 31, 2020 | 105,794 | 1,880 | 1.81% |
Dec 31, 2019 | 103,914 | -21,247 | -16.98% |
Dec 31, 2018 | 125,161 | 3,564 | 2.93% |
Dec 31, 2017 | 121,597 | 3,204 | 2.71% |
Dec 31, 2016 | 118,393 | -307 | -0.26% |
Dec 31, 2015 | 118,700 | -14,713 | -11.03% |
Dec 31, 2014 | 133,413 | -2,283 | -1.68% |
Dec 31, 2013 | 135,696 | 7,972 | 6.24% |
Dec 31, 2012 | 127,724 | 4,038 | 3.26% |
Dec 31, 2011 | 123,686 | 4,268 | 3.57% |
Dec 31, 2010 | 119,418 | 19,584 | 19.62% |
Dec 31, 2009 | 99,834 | 3,117 | 3.22% |
Dec 31, 2008 | 96,717 | -1,483 | -1.51% |
Dec 31, 2007 | 98,200 | -2,535 | -2.52% |
Dec 31, 2006 | 100,735 | 9,735 | 10.70% |
Dec 31, 2005 | 91,000 | 9,600 | 11.79% |
Dec 31, 2004 | 81,400 | 2,859 | 3.64% |
Dec 31, 2003 | 78,541 | 5,664 | 7.77% |
Dec 31, 2002 | 72,877 | 2,557 | 3.64% |
Dec 31, 2001 | 70,320 | 1,252 | 1.81% |
Dec 31, 2000 | 69,068 | -13,391 | -16.24% |
Dec 31, 1999 | 82,459 | -3,376 | -3.93% |
Dec 31, 1998 | 85,835 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Thermo Fisher | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Pfizer | 88,000 |
Merck & Co. | 72,000 |
Danaher | 63,000 |
AbbVie | 50,000 |
Amgen | 26,700 |
NVS News
- 2 days ago - Some 330 jobs hit as Novartis closes Morphosys, WiWo reports - Reuters
- 8 days ago - Novartis: Time To Increase - Seeking Alpha
- 11 days ago - Longer-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer - GlobeNewsWire
- 13 days ago - Longer-term data for Novartis Scemblix® reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML - GlobeNewsWire
- 14 days ago - 12 High-Yield Dividend Aristocrats To Weather The Coming 2025 Storm In Style - Seeking Alpha
- 15 days ago - New Phase IIIB data shows Novartis Fabhalta® improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapy - GlobeNewsWire
- 17 days ago - Novartis cannot block generic of best-selling heart drug, US appeals court says - Reuters
- 19 days ago - Olema: Cash Infusion And Supply Agreement With Novartis Carries The Tide Forward - Seeking Alpha